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Letter to the EditorReply to: ‘‘Global trends in mortality from
intrahepatic and extrahepatic cholangiocarcinoma’’To the Editor:
We thank Dr. Khan et al. for their interest in our work.1 They are
right in pointing out that trends in extrahepatic cholangiocarci-
noma (ECC) mirror the long-term declines in gallbladder
cancer,2,3 due to the increase in cholecystectomy. Gallbladder
cancer mortality rates in the European Union, in fact, have been
declining in women from 2.52/100,000 (world standard) in
1990 to 1.24 in 2015 (51%). Comparable figures in men were
1.65 in 1990 and 1.24 in 2015 (25%).4
We agree that misclassification in cancer registration, death
coding and certification may have affected the incidence and
mortality rates of intrahepatic cholangiocarcinoma (ICC), ECC
and, mainly, their subsites. The WHO dataset did not enable
the subsites of ECC to be distinguished, and the complex of hilar
and perihilar CC is a larger proportion than the ‘‘historic
Klatskin’s tumors”.5 However, due to the small overall propor-
tion of Klatskin’s tumors reported using current methodology,
this misclassification is not likely to materially affect the overall
ICC/ECC trends.6
We also agree with the plea by Dr. Khan et al. that further
attention should be given to the diagnosis, classification and
registration of ICC and ECC, and their subsites, by hepatologists,
pathologists, cancer registration and death certification
systems.Conflict of interest
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